Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Illumina $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
MediaAlpha $370.3 million secondary offering
We advised the underwriters on the SEC-registered stock offering
Oncopeptides SEK 1.1 billion private placing of new shares
We advised Oncopeptides on the private placement of shares
Oak Street Health $920 million convertible senior notes offering
We advised the initial purchasers on the Rule 144A offering
Prometheus Biosciences $218.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Avid Bioservices $143.8 million exchangeable senior notes offering
We advised the initial purchasers on the Rule 144A offering
Jounce Therapeutics $64.7 million follow-on offering
We advised the underwriters on the equity offering
Owens & Minor $500 million notes offering
We advised the initial purchasers on the high-yield notes offering
Nurix Therapeutics $160.4 million follow-on offering
We advised the underwriters on the equity offering
Oscar Health $200 million revolving credit facility
We advised the administrative agent in connection with the facility